Search

everythinglearnresearchcommunity

for

Search:↓

A risk prediction model can help diagnose systemic lupus erythematosus earlier in primary care.

Chemotherapy can cause permanent, non-reversible hair loss similar to pattern baldness.

COVID-19 vaccination may trigger lupus in some people.

SLE is more common among Nigerians than previously thought, especially in women, requiring early treatment.

Fibroblast changes in systemic sclerosis may help understand disease severity and treatment.

Hair loss is common in lupus patients and can be permanent or reversible, depending on the type, with various treatments available.

No systemic treatment for alopecia areata has strong evidence of effectiveness.

Hair loss in lupus patients indicates higher disease activity.

Early detection and stopping the drug are key to managing DRESS, and careful monitoring is important due to possible severe reactions.

Most Korean systemic lupus erythematosus patients experienced hair loss, often as non-scarring diffuse hair loss, with non-scarring patch alopecia also common.

SLE patients in eastern Saudi Arabia have a generally good prognosis despite multi-organ involvement.

Systemic Lupus Erythematosus has varied symptoms and is hard to diagnose, affecting many body parts and requiring careful clinical judgment.

The document concludes that anti-dsDNA antibodies are not unique to SLE and their use as indicators is doubtful, highlighting the need for better understanding and classification of the disease.

Hair loss in lupus is different from hair loss in alopecia areata and may indicate lupus activity.

Systemic corticosteroids don't prevent severe alopecia areata from spreading or relapsing.

Trichoscopy is useful for diagnosing and monitoring systemic lupus erythematosus, with certain hair and scalp changes indicating more active disease.

Topical clobetasol is recommended over mycophenolate mofetil for treating Lichen Planopilaris due to better safety and patient satisfaction.

Catalytic antibodies are early indicators and active participants in the development of systemic lupus erythematosus.

Systemic diseases can cause hair loss, which is often reversible with treatment.

Systemic lupus erythematosus is a chronic disease causing inflammation and various symptoms, mainly in young women, treated with anti-inflammatory and immunosuppressive drugs.

Most patients with Systemic Lupus Erythematosus experience fatigue, skin issues, and joint pain.

The study created a skin model with realistic blood vessels that improves skin grafts and testing for drug delivery.

Systemic retinoids are effective for psoriasis but have side effects; benefits may outweigh risks, especially when reducing cancer risks from other treatments.

Testosterone can help premenopausal and postmenopausal women with low sexual desire, but its long-term safety is unclear and it's not widely approved for this use.

Using systemic drugs as creams for skin conditions shows promise, but more research is needed to confirm their effectiveness and safety.

Some skin medications can harm male fertility, but they don't seem to cause birth defects from father's exposure.

The article concludes that correctly diagnosing systemic causes of hair loss requires a detailed clinical evaluation and a systematic diagnostic approach.

A woman with lupus and severe nerve damage improved with specific treatments.

Adding a small amount of TPGS to minoxidil can help hair growth, but too much TPGS reduces this effect and increases minoxidil in the blood.

Baricitinib might help treat hair loss in lupus patients, but more research is needed.